Teleflex Incorporated (TFX) Director Stephen K. M.D. Klasko Sells 200 Shares

Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total transaction of $49,792.00. Following the transaction, the director now owns 8,080 shares of the company’s stock, valued at $2,011,596.80. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Teleflex Incorporated (NYSE:TFX) traded up $1.91 on Thursday, hitting $256.64. 188,000 shares of the company traded hands, compared to its average volume of 246,200. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70. Teleflex Incorporated has a twelve month low of $159.64 and a twelve month high of $271.23. The firm has a market capitalization of $11,475.40, a PE ratio of 46.83, a PEG ratio of 1.88 and a beta of 1.09.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.11. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The business had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. During the same period last year, the company earned $1.80 earnings per share. The company’s quarterly revenue was up 17.3% on a year-over-year basis. research analysts expect that Teleflex Incorporated will post 8.35 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Wednesday, November 15th were given a $0.34 dividend. The ex-dividend date of this dividend was Tuesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. Teleflex’s dividend payout ratio is presently 24.82%.

Several equities analysts have weighed in on TFX shares. KeyCorp restated a “hold” rating on shares of Teleflex in a report on Wednesday, September 6th. Morgan Stanley upgraded shares of Teleflex from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $220.00 to $274.00 in a report on Wednesday, September 6th. Leerink Swann upgraded shares of Teleflex from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $227.00 to $266.00 in a report on Thursday, September 7th. Jefferies Group lifted their price target on shares of Teleflex from $253.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Finally, Zacks Investment Research downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, September 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $274.44.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TFX. Victory Capital Management Inc. boosted its position in shares of Teleflex by 21.0% in the second quarter. Victory Capital Management Inc. now owns 7,325 shares of the medical technology company’s stock worth $1,522,000 after acquiring an additional 1,269 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Teleflex by 120.6% during the second quarter. Robeco Institutional Asset Management B.V. now owns 1,496 shares of the medical technology company’s stock valued at $310,000 after buying an additional 818 shares in the last quarter. Neuberger Berman Group LLC lifted its position in Teleflex by 0.5% during the second quarter. Neuberger Berman Group LLC now owns 5,708 shares of the medical technology company’s stock valued at $1,186,000 after buying an additional 28 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Teleflex by 21.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,235 shares of the medical technology company’s stock valued at $1,503,000 after buying an additional 1,286 shares in the last quarter. Finally, Commerce Bank acquired a new position in Teleflex during the second quarter valued at approximately $400,000. 88.97% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Teleflex Incorporated (TFX) Director Stephen K. M.D. Klasko Sells 200 Shares” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://transcriptdaily.com/2018/01/04/teleflex-incorporated-tfx-director-stephen-k-m-d-klasko-sells-200-shares.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply